IMA402 Combination in Lung Cancer

Source · https://www.globenewswire.com/news-release/2026/05/31/3303923/0/en/Immatics-Presents-Data-on-IMA401-MAGEA4-8-Bispecific-at-2026-ASCO-Annual-Meeting-with-Simultaneous-Publication-in-Nature-Medicine-Supporting-Development-of-IMA401-IMA402-Combinatio.html

Read source

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

Story key points

0 claims · impact-rated

What matters in this story

No key-points head found for this article.

Ticker attribution

Model heads

Sentiment in this article

No ticker sentiment head found.

Relationships in this article

No ticker relationship head found.

Impact vectors

0 dimensions · 9 clusters

Analytical profile by cluster

Macro Sensitivity+0.000
Sector Rotation+0.000

News Impact Screener — Catch market-moving news before the crowd

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

What matters in this story

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

What matters in this story

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted